Science AI Journal
Medicine · Research topic

Open research questions in Acute Lymphoblastic Leukemia research

45 unresolved questions extracted from the limitations and future-work sections of 224 Acute Lymphoblastic Leukemia research papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Further clinical studies should refine rescue strategies to optimize efficacy and minimize toxicity. The study suggests that adjustments to FA dosing post-GP may be warranted due to partial FA degradation.

    Glucarpidase efficacy in mitigating methotrexate toxicity is unaffected by concurrent administration of folinic acid · 2026 · DOI

  • The current guidelines recommend pausing FA around GP administration due to presumed interference, but the actual impact of FA on GP efficacy is unknown. The study aims to fill this knowledge gap by investigating the effects of FA on GP activity.

    Glucarpidase efficacy in mitigating methotrexate toxicity is unaffected by concurrent administration of folinic acid · 2026 · DOI

  • Acute neurotoxicity is a significant adverse event in pediatric patients with ALL. The causes of acute neurotoxicity are not well understood. There is a need to develop strategies to prevent and manage acute neurotoxicity.

    Etiological Profile and Clinical Outcomes Of Acute Neurotoxicity During Pediatric ALL Treatment in a Developing Country · 2026 · DOI

  • The study faced challenges in collecting and analyzing data from a limited sample size. The study had to overcome the challenge of detecting copy number alterations (CNAs) in ALL patients. The study faced the challenge of interpreting the prognostic significance of biomarker expression in ALL patients.

    Combination of p-STAT5, CRLF2 and copy number alterations as a potential indicator of a high-risk subgroup of acute lymphoblastic leukemia · 2026 · DOI

  • Haematological toxicity is a significant challenge in treating children with ALL. Hyperleukocytosis at diagnosis is associated with increased relapse risk. Treatment delays and need for blood product support are common.

    Outcomes of an acute lymphoblastic leukaemia cohort between 2008 and 2017 at a South African paediatric oncology unit · 2026 · DOI

  • BACKGROUND: Hypoglycemia is a rarely reported complication of asparaginase (ASP) therapy in children with acute lymphoblastic leukemia/lymphoma (ALL/LLy).

    Recurrent Hypoglycemia Following Asparaginase Therapy for Lymphoid Malignancies in Childhood: The Texas Children's Hospital Experience · 2026 · DOI

  • Standard intensive supportive care often fails to halt progressive organ damage, while clinical data regarding therapeutic plasma exchange (TPE) as a rescue intervention in pediatric populations remain scarce.

    Single-session therapeutic plasma exchange as salvage therapy for pegaspargase-induced severe acute pancreatitis accompanied by multiple organ dysfunction in a pediatric patient with B-cell precursor acute lymphoblastic leukemia: a case report · 2026 · DOI

  • Inherited genetic variation substantially increases the risk for developing childhood B-cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children, yet the underlying mechanisms remain poorly understood.

    Single-cell multiomic mapping of genetic predisposition to childhood B-cell acute lymphoblastic leukemia · 2026 · DOI

  • B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, yet the mechanisms by which inherited risk variants predispose to leukemia development remain poorly understood.

    A functional genomics screen of human B-cell differentiation reveals convergent mechanisms of inherited childhood leukemia predisposition · 2026 · DOI

  • 997), supporting the broad generalisability of identified variants, which remains to be evaluated prospectively.

    Pharmacogenetic Predictors of Chemotherapy Treatment-Related Toxicities in Paediatric and Adolescent Acute Lymphoblastic Leukemia: A Systematic Review, Meta-Analysis and Literature-Based Candidate Prioritization · 2026 · DOI

  • There is a lack of studies on the use of chidamide as maintenance therapy in T-ALL/T-LBL patients after allo-HSCT. The efficacy and safety of chidamide in this setting are unknown.

    Safety and efficacy of chidamide for maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with T-ALL/T-LBL · 2026 · DOI

  • There is a lack of publications on the use of blinatumomab in pediatric B-ALL. There is a need for more research on the safety and effectiveness of blinatumomab in an outpatient setting.

    Ambulatory use of blinatumomab in paediatric patients with relapsed or refractory B-cell acute lymphoblastic leukaemia at a single centre in South Africa · 2026 · DOI

  • Further studies are needed to investigate the clinical potential of targeting drug efflux and DNA repair to enhance IO activity. Additional studies are needed to explore the mechanisms of IO resistance and develop effective therapeutic strategies.

    Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines · 2026 · DOI

  • The mechanisms of IO resistance are not fully understood. There is a need for effective therapeutic strategies to overcome IO resistance.

    Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines · 2026 · DOI

  • Existing population pharmacokinetic models may not accurately characterize methotrexate clearance due to differences in patient characteristics. A reliable population pharmacokinetic model is needed for accurate personalized dosing.

    Development and validation of high-dose methotrexate population pharmacokinetic models to inform clinical decisions on dosing · 2026 · DOI

  • Determining what chemical exposures are toxic to children requires a variety of research approaches. Each center consists of three to four unique but integrated research projects related to the center’s theme. Children’s Centers are supported by cores that provide infrastructure, services, and resources to the research projects to help them meet their long–term goals. Each center is structured with at least two cores: one that coordinates and integrates center activities, and one that engages with the community and translates scientific findings. A coordinated interrelationship exists between the projects and cores that combine to form a cohesive center with a common theme. The Children’s Centers examine pressing questions with a wide-angle lens, not allowing the boundaries of any particular field to restrict, define, or determine the array of possible approaches.

    Environmental Pesticide Exposure in the Etiology of Pediatric Brain Tumors and Leukemia: A Scoping Review of Epidemiological Studies · 2026 · DOI

  • There is a need to understand the causes and outcomes of acute neurotoxicity in pediatric patients with ALL. The existing literature has limitations, including short follow-up periods and limited sample sizes.

    Etiological Profile and Clinical Outcomes Of Acute Neurotoxicity During Pediatric ALL Treatment in a Developing Country · 2026 · DOI

  • There is a need to investigate the relationship between endocan levels and remission status in acute leukemia patients. There is a lack of studies assessing the potential prognostic significance of endocan levels in acute leukemia.

    Early assessment of endocan level as a predictor of remission status in acute leukemia patients · 2026 · DOI

  • Overall, these findings contribute to the understanding of endocan level potential prognostic significance in acute leukemia patients and warrant further exploration of its role in leukemogenesis. The study emphasizes the need for larger sample sizes and further investigation into the interplay between endocan level and non-remission in acute leukemia patients.

    Early assessment of endocan level as a predictor of remission status in acute leukemia patients · 2026 · DOI

  • The mechanisms underlying leukemia development and progression are not fully understood. The in utero origin and two-hit hypotheses in pediatric ALL need further clinical evidence.

    Concordant ETV6::RUNX1-positive acute lymphoblastic leukemia in monozygotic twins: a case report and review of the literature · 2026 · DOI

  • Limited blood volume is a challenge in pediatrics. Pre-analytical variability is a challenge in liquid biopsy. Standardization issues and ethical considerations are limitations in pediatrics.

    Liquid biopsy in pediatric acute lymphoblastic leukemia · 2026 · DOI

  • There is a need for further validation of liquid biopsy technologies in pediatric ALL. There is a lack of standardization in liquid biopsy protocols. There is a need for more research on the use of machine learning models in liquid biopsy.

    Liquid biopsy in pediatric acute lymphoblastic leukemia · 2026 · DOI

  • The study had a limited sample size of 115 patients. The study only included precursor-B-ALL patients. The follow-up period ranged from 0.1 to 34 months.

    Combination of p-STAT5, CRLF2 and copy number alterations as a potential indicator of a high-risk subgroup of acute lymphoblastic leukemia · 2026 · DOI

  • Germline loss-of-function variants cause Noonan syndrome, with emerging evidence implicating LZTR1 in predisposition to childhood acute lymphoblastic leukemia (ALL), though its role in hematopoiesis remains poorly defined.

    LZTR1 functions as a two-hit tumor suppressor in childhood acute lymphoblastic leukemia · 2026 · DOI

  • The gap in understanding the genomic background of ETP-ALL. The need for accurate diagnosis and strict application of the WHO lineage assignment criteria.

    Case Report: Early T-cell precursor acute lymphoblastic leukemia with aberrant CD19 expression and an NPM1 mutation · 2026 · DOI

Most-cited papers in Acute Lymphoblastic Leukemia research

Most recent work

Find a gap in your own Acute Lymphoblastic Leukemia research sub-topic

This page shows what the Acute Lymphoblastic Leukemia research literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
1,213 open questions
Artificial Intelligence in Healthcare and Education
1,153 open questions
Physical Activity and Health
718 open questions
Dementia and Cognitive Impairment Research
565 open questions
Attention Deficit Hyperactivity Disorder
544 open questions
Smoking Behavior and Cessation
532 open questions
Innovations in Medical Education
480 open questions
HIV/AIDS Research and Interventions
472 open questions
45 open questions have been extracted from the limitations and future-work passages of 224 Acute Lymphoblastic Leukemia research papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.